Key result
Resection plus targeted immunotherapy controls rare metastatic splenic angiosarcoma with cardiac involvement.
Why the study?
Splenic angiosarcoma is a rare, highly malignant tumor with atypical early symptoms and a dismal prognosis, warranting attention regarding its diagnosis and treatment.
Does laparoscopic splenectomy and partial hepatectomy followed by targeted immunotherapy improve outcomes in a patient with splenic angiosarcoma with hepatic and cardiac metastases?
Case Report (n=1)
No
Does laparoscopic splenectomy and partial hepatectomy followed by targeted immunotherapy improve outcomes in a patient with splenic angiosarcoma with hepatic and cardiac metastases?
This case report highlights a rare presentation of splenic angiosarcoma with concurrent hepatic and right atrial metastases, demonstrating the use of multimodal imaging and combined surgical and targeted immunotherapy.
Multifocal splenic angiosarcoma with right atrial metastasis warrants multidisciplinary evaluation; leaves open optimal sequencing of surgery and systemic therapy.
Splenic angiosarcoma (SA) is an rare malignant tumor in clinical practice, characterized by high malignancy, atypical early symptoms, and a dismal prognosis. In recent years, growing attention has been focused on its diagnosis and treatment. This report describes a patient who was admitted to the hospital due to left upper abdominal pain. Contrast-enhanced CT indicated unevenly enhanced tumors in the spleen, liver, and right atrium. The patient was treated with laparoscopic splenectomy + partial hepatectomy and was diagnosed based on postoperative pathology and immunohistochemistry (positive for CD31 and CD34). After the operation, anlotinib + toripalimab targeted immunotherapy was used, and the patient recovered well. This case suggests that SA is prone to metastasis in the early stage. Clinically, the diagnosis of SA requires a combination of pathological diagnosis and imaging diagnosis, and postoperative targeted immunotherapy may improve the prognosis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted a case report in Splenic angiosarcoma with hepatic and cardiac metastases (n=1). Surgery (splenectomy and partial hepatectomy) and targeted immunotherapy (anlotinib + toripalimab) was evaluated on Clinical outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: